{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T17:28:08Z","timestamp":1785605288128,"version":"3.56.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006447","name":"Universit\u00e4t Z\u00fcrich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["F32CA189372"],"award-info":[{"award-number":["F32CA189372"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007856","name":"Baylor College of Medicine","doi-asserted-by":"publisher","award":["B16-HER2"],"award-info":[{"award-number":["B16-HER2"]}],"id":[{"id":"10.13039\/100007856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008375","name":"Universit\u00e4t Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.omtm.2021.01.002","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T23:34:30Z","timestamp":1611099270000},"page":"572-586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy"],"prefix":"10.1016","volume":"20","author":[{"given":"Dominik","family":"Br\u00fccher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Kirchhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena N.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatina","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Kolibius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C.","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs F.","family":"Greber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Zippelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pl\u00fcckthun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2021.01.002_bib1","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1002\/cam4.2148","article-title":"Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities","volume":"8","author":"Sedighi","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.omtm.2021.01.002_bib2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41556-019-0344-z","article-title":"Advances in stem cell research and therapeutic development","volume":"21","author":"De Luca","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.omtm.2021.01.002_bib3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/cancers10060201","article-title":"Designer oncolytic adenovirus: coming of age","volume":"10","author":"Baker","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omtm.2021.01.002_bib4","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1002\/1873-3468.13691","article-title":"State-of-the-art human adenovirus vectorology for therapeutic approaches","volume":"593","author":"Gao","year":"2019","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omtm.2021.01.002_bib5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/diseases6020042","article-title":"Viral vectors in gene therapy","volume":"6","author":"Lundstrom","year":"2018","journal-title":"Diseases"},{"key":"10.1016\/j.omtm.2021.01.002_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-virology-092818-015550","article-title":"Adenovirus entry: from infection to immunity","volume":"6","author":"Greber","year":"2019","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.omtm.2021.01.002_bib7","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/1873-3468.13849","article-title":"Adenoviruses\u2013infection, pathogenesis and therapy","volume":"594","author":"Greber","year":"2020","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omtm.2021.01.002_bib8","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines (Basel)"},{"issue":"s1","key":"10.1016\/j.omtm.2021.01.002_bib9","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.3233\/JPD-181485","article-title":"Repairing the brain: gene therapy","volume":"8","author":"Bj\u00f6rklund","year":"2018","journal-title":"J.\u00a0Parkinsons Dis."},{"key":"10.1016\/j.omtm.2021.01.002_bib10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/d41573-018-00016-1","article-title":"Gene therapies in ophthalmic disease","volume":"18","author":"Gordon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtm.2021.01.002_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3390\/biomedicines2020149","article-title":"Gene therapy used in cancer treatment","volume":"2","author":"Wirth","year":"2014","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtm.2021.01.002_bib12","doi-asserted-by":"crossref","first-page":"17113","DOI":"10.1038\/s41598-017-17180-w","article-title":"CRISPR\/Cas9 delivery with one single adenoviral vector devoid of all viral genes","volume":"7","author":"Ehrke-Schulz","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2021.01.002_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.omtm.2020.01.014","article-title":"A single \u201call-in-one\u201d helper-dependent adenovirus to deliver donor DNA and CRISPR\/Cas9 for efficient homology-directed repair","volume":"17","author":"Palmer","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2021.01.002_bib14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/sj.cgt.7700436","article-title":"Cancer therapy utilizing an adenoviral vector expressing only E1A","volume":"9","author":"Hubberstey","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omtm.2021.01.002_bib15","doi-asserted-by":"crossref","first-page":"16008","DOI":"10.1038\/mtm.2016.8","article-title":"Treatment of osteoarthritis using a helper-dependent adenoviral vector retargeted to chondrocytes","volume":"3","author":"Ruan","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2021.01.002_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.copbio.2020.05.008","article-title":"Gene delivery for immunoengineering","volume":"66","author":"Neshat","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.omtm.2021.01.002_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","article-title":"Dissecting the mechanisms of immune checkpoint therapy","volume":"20","author":"Sharma","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omtm.2021.01.002_bib18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2021.01.002_bib19","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2021.01.002_bib20","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2021.01.002_bib21","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.omtm.2021.01.002_bib22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1126\/scitranslmed.aat7807","article-title":"The hallmarks of successful anticancer immunotherapy","volume":"10","author":"Galluzzi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2021.01.002_bib23","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful anti-PD-1 cancer immunotherapy requires T\u00a0cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.omtm.2021.01.002_bib24","doi-asserted-by":"crossref","first-page":"m736","DOI":"10.1136\/bmj.m736","article-title":"Autoimmune complications of immunotherapy: pathophysiology and management","volume":"369","author":"Chan","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.omtm.2021.01.002_bib25","doi-asserted-by":"crossref","first-page":"eaax5032","DOI":"10.1126\/sciadv.aax5032","article-title":"Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer","volume":"6","author":"Huang","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtm.2021.01.002_bib26","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.ymthe.2020.02.016","article-title":"Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T\u00a0cells to control the growth of heterogeneous tumors","volume":"28","author":"Porter","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.01.002_bib27","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1126\/scitranslmed.aax7992","article-title":"Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade","volume":"12","author":"Nakao","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"Suppl 5","key":"10.1016\/j.omtm.2021.01.002_bib28","first-page":"001","article-title":"Helper-dependent adenoviral vectors","author":"Rosewell","year":"2011","journal-title":"J.\u00a0Genet. Syndr. Gene Ther."},{"key":"10.1016\/j.omtm.2021.01.002_bib29","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1089\/hum.2013.071","article-title":"Transgene expression up to 7 years in nonhuman primates following hepatic transduction with helper-dependent adenoviral vectors","volume":"24","author":"Brunetti-Pierri","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.01.002_bib30","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1128\/JVI.78.11.5966-5972.2004","article-title":"Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in\u00a0vivo","volume":"78","author":"Muruve","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2021.01.002_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0299-y","article-title":"No more helper adenovirus: production of gutless adenovirus (GLAd) free of adenovirus and replication-competent adenovirus (RCA) contaminants","volume":"51","author":"Lee","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.omtm.2021.01.002_bib32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nprot.2009.4","article-title":"A rapid protocol for construction and production of high-capacity adenoviral vectors","volume":"4","author":"Jager","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtm.2021.01.002_bib33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-1-61779-095-9_6","article-title":"Manufacturing of adenovirus vectors: production and purification of helper dependent adenovirus","volume":"737","author":"Dormond","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtm.2021.01.002_bib34","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/jgm.301","article-title":"Production of helper-dependent adenovirus vector relies on helper virus structure and complementing","volume":"4","author":"Zhou","year":"2002","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omtm.2021.01.002_bib35","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1073\/pnas.97.3.1002","article-title":"Optimization of the helper-dependent adenovirus system for production and potency in\u00a0vivo","volume":"97","author":"Sandig","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2021.01.002_bib36","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ymthe.2003.08.014","article-title":"Improved system for helper-dependent adenoviral vector production","volume":"8","author":"Palmer","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.01.002_bib37","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/1873-3468.13731","article-title":"Retargeting adenoviruses for therapeutic applications and vaccines","volume":"594","author":"Barry","year":"2020","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omtm.2021.01.002_bib38","doi-asserted-by":"crossref","first-page":"E869","DOI":"10.1073\/pnas.1213653110","article-title":"Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters","volume":"110","author":"Dreier","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2021.01.002_bib39","doi-asserted-by":"crossref","first-page":"e01112","DOI":"10.1128\/JVI.01112-20","article-title":"Fusion of large polypeptides to human adenovirus type 5 capsid protein IX can compromise virion stability and DNA packaging capacity","volume":"94","author":"Poulin","year":"2020","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2021.01.002_bib40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-1-61779-379-0_15","article-title":"Rapid selection of high-affinity binders using ribosome display","volume":"805","author":"Dreier","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtm.2021.01.002_bib41","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.3107","article-title":"Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement","volume":"19","author":"Xu","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2021.01.002_bib42","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1002\/1873-3468.13649","article-title":"Interaction of adenovirus with antibodies, complement, and coagulation factors","volume":"593","author":"Allen","year":"2019","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omtm.2021.01.002_bib43","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41467-017-02707-6","article-title":"Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control","volume":"9","author":"Schmid","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2021.01.002_bib44","doi-asserted-by":"crossref","first-page":"e10611","DOI":"10.1371\/journal.pone.0010611","article-title":"Systematic comparison of constitutive promoters and the doxycycline-inducible promoter","volume":"5","author":"Qin","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2021.01.002_bib45","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/19420862.2015.1008351","article-title":"Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells","volume":"7","author":"Chng","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.omtm.2021.01.002_bib46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5493\/wjem.v5.i1.11","article-title":"Internal ribosome entry site-based vectors for combined gene therapy","volume":"5","author":"Renaud-Gabardos","year":"2015","journal-title":"World J. Exp. Med."},{"key":"10.1016\/j.omtm.2021.01.002_bib47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nmeth.1318","article-title":"Enzymatic assembly of DNA molecules up to several hundred kilobases","volume":"6","author":"Gibson","year":"2009","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omtm.2021.01.002_bib48","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/mt.2010.176","article-title":"Helper-dependent adenoviral vectors are superior in\u00a0vitro to first-generation vectors for endothelial cell-targeted gene therapy","volume":"18","author":"Flynn","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.01.002_bib49","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1128\/JVI.79.2.1053-1061.2005","article-title":"Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs","volume":"79","author":"Shayakhmetov","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2021.01.002_bib50","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00262-019-02377-x","article-title":"Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone","volume":"68","author":"Rafei-Shamsabadi","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omtm.2021.01.002_bib51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/10430340460732445","article-title":"Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates","volume":"15","author":"Brunetti-Pierri","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.01.002_bib52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (aldesleukin)\u2014expert consensus on best management practices-2014","volume":"2","author":"Dutcher","year":"2014","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omtm.2021.01.002_bib53","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1006\/mthe.2000.0050","article-title":"IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector","volume":"1","author":"Mizuguchi","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.01.002_bib54","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.omtm.2021.01.002_bib55","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fonc.2019.00297","article-title":"Gene therapy leaves a vicious cycle","volume":"9","author":"Goswami","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omtm.2021.01.002_bib56","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1128\/JVI.01644-08","article-title":"DNA genome size affects the stability of the adenovirus virion","volume":"83","author":"Smith","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2021.01.002_bib57","doi-asserted-by":"crossref","first-page":"13565","DOI":"10.1073\/pnas.93.24.13565","article-title":"A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal","volume":"93","author":"Parks","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2021.01.002_bib58","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0092-8674(84)90453-7","article-title":"Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism","volume":"39","author":"Emerman","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2021.01.002_bib59","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omtm.2021.01.002_bib60","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what\u2019s important?","volume":"10","author":"Fausther-Bovendo","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.omtm.2021.01.002_bib61","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/nprot.2007.135","article-title":"A protocol for rapid generation of recombinant adenoviruses using the AdEasy system","volume":"2","author":"Luo","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtm.2021.01.002_bib62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40425-018-0464-1","article-title":"A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer","volume":"7","author":"D\u2019Amico","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omtm.2021.01.002_bib63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00262-011-1090-7","article-title":"Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment","volume":"61","author":"Wang","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omtm.2021.01.002_bib64","doi-asserted-by":"crossref","first-page":"D781","DOI":"10.1093\/nar\/gkj088","article-title":"IMGT\/LIGM-DB, the IMGT comprehensive database of immunoglobulin and T\u00a0cell receptor nucleotide sequences","volume":"34","author":"Giudicelli","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2021.01.002_bib65","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.molimm.2014.09.017","article-title":"Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A\/L235A and N297A Fc mutations engineered into mouse IgG2a","volume":"63","author":"Arduin","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omtm.2021.01.002_bib66","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1074\/jbc.M116.767749","article-title":"Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice","volume":"292","author":"Lo","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2021.01.002_bib67","doi-asserted-by":"crossref","first-page":"e0116878","DOI":"10.1371\/journal.pone.0116878","article-title":"Optimization of heavy chain and light chain signal peptides for high level expression of therapeutic antibodies in CHO cells","volume":"10","author":"Haryadi","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2021.01.002_bib68","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nbt1087","article-title":"Stable antibody expression at therapeutic levels using the 2A peptide","volume":"23","author":"Fang","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2021.01.002_bib69","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00262-008-0451-3","article-title":"Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity","volume":"57","author":"Simmons","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omtm.2021.01.002_bib70","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/sj.mt.6300142","article-title":"An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in\u00a0vivo","volume":"15","author":"Fang","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.01.002_bib71","doi-asserted-by":"crossref","first-page":"1792084","DOI":"10.1080\/19420862.2020.1792084","article-title":"Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness","volume":"12","author":"Br\u00fccher","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.omtm.2021.01.002_bib72","first-page":"e52894","article-title":"Cloning and large-scale production of high-capacity adenoviral vectors based on the human adenovirus type 5","volume":"107","author":"Ehrke-Schulz","year":"2016","journal-title":"J.\u00a0Vis. Exp."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050121000024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050121000024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:24:34Z","timestamp":1762421074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050121000024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":72,"alternative-id":["S2329050121000024"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2021.01.002","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2021.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s).","name":"copyright","label":"Copyright"}]}}